Abstract
Lapatinib ditosylate, an ErbB-2 and EGFR dual tyrosine kinase inhibitor, is being developed by GlaxoSmithKline plc for the potential treatment of solid tumors.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / therapeutic use*
-
Clinical Trials as Topic / statistics & numerical data
-
Drugs, Investigational / chemistry
-
Drugs, Investigational / therapeutic use*
-
Furans / chemistry
-
Furans / therapeutic use*
-
Humans
-
Neoplasms / drug therapy
-
Quinazolines / chemistry
-
Quinazolines / therapeutic use*
-
Technology, Pharmaceutical / methods*
Substances
-
Antineoplastic Agents
-
Drugs, Investigational
-
Furans
-
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
-
Quinazolines